Rituximab in juvenile myasthenia gravis-an international cohort study and literature review

Sithara Ramdas*, Adela Della Marina, Monique M. Ryan, Kenneth McWilliam, Andrea Klein, David Jacquier, Setareh Alabaf, Anne Marie Childs, Deepak Parasuraman, David Beeson, Jacqueline Palace, Heinz Jungbluth

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

5 Citations (Scopus)


Juvenile myasthenia gravis (JMG) is a rare, antibody-mediated disorder of the neuromuscular junction. Treatment strategies in JMG are largely informed by adult MG treatments as the pathophysiology is similar. Rituximab is increasingly considered as a treatment option in refractory JMG but has not yet been systematically investigated in this patient group We conducted a retrospective study from five international centres with expertise in paediatric myasthenia. 10 JMG patients treated with rituximab were identified. Following rituximab treatment all patients had a reduction in JMG-related hospital admissions. At 24 month follow up, 6 patients (60%) had achieved complete stable remission or pharmacological remission and 7 patients were able to reduce immunomodulatory treatment(s). The main side-effect was infusion-related reactions (30%) which resolved in all patients with symptomatic treatment. We compared our cohort to previously reported JMG cases treated with rituximab and noted similar response rates but a slightly higher side-effect profile. Rituximab is a safe and effective treatment option in moderate to severe JMG and most patients have an improvement in MG symptoms post treatment.

Original languageEnglish
Pages (from-to)5-10
Number of pages6
JournalEuropean Journal of Paediatric Neurology
Publication statusPublished - Sept 2022


  • Juvenile myasthenia gravis
  • Myasthenia gravis
  • Paediatric
  • Rituximab


Dive into the research topics of 'Rituximab in juvenile myasthenia gravis-an international cohort study and literature review'. Together they form a unique fingerprint.

Cite this